目的 探讨复方嗜酸乳杆菌联合曲美布汀治疗腹泻型肠易激综合症的临床疗效.方法 选择上海市浦东新区光明中医医院2013 年6 月-2014 年6 月收治的120 例腹泻型肠易激综合征患者,随机分为对照组(60 例)和治疗组(60 例).对照组饭前30 min 口服给予马来酸曲美布汀片0.1 g/次,3 次/d.治疗组在对照组的基础上饭后口服给予复方嗜酸乳杆菌片1 g/次,3 次/d.对照组和治疗组患者均连续治疗1 个月.观察两组患者的临床疗效,同时记录腹痛积分、腹泻积分、大便性状异常化率和日均排便次数,检测血清中的白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)水平.结果 治疗后,对照组和治疗组的总有效率分别为80.0%、93.3%,,两组总有效率比较差异有统计学意义(P< 0.05).治疗后两组的腹痛积分、腹泻积分、大便性状异常化率和日均排便次数均较治疗前显著降低(P< 0.05);治疗组治疗后的腹痛积分、腹泻积分、大便性状异常化率和日均排便次数均较对照组治疗后显著降低(P< 0.05).治疗后两组血清中的IL-6 和TNF-α 水平较治疗前显著降低(P< 0.05);治疗后治疗组血清中的IL-6 和TNF-α 水平较对照组显著降低(P< 0.05).结论 复方嗜酸乳杆菌片联合马来酸曲美布汀片治疗腹泻型肠易激综合征具有显著的临床疗效,安全性较高,具有一定的临床推广价值.

Objective To explore the effect of Compound Eosinophil-Lactobacillus Tablets combined with trimebutine in treatment of diarrhea-predominant irritable bowel syndrome. Methods Patients (120 cases) with diarrhea-predominant irritable bowel syndrome in Pudong New Area Guangming Hospital of Traditional Chinese Medicine from June 2013 to June 2014 were randomly divided into control and treatment groups, and each group had 60 cases. The patients in the control group were po administered with Trimebutine Maleate Tablets 30 min before meals, 0.1 g/time, three times daily. The patients in the treatment group were po administered with Compound Eosinophil-Lactobacillus Tablets after meals on the basis of control group, 1 g/time, three times daily. The patients in the control and treatment groups were treated for 1 month. After treatment, the efficacy was evaluated, and abdominal pain score, diarrhea score, abnormal rate of stool characteristics, and defecating frequency were recorded. At the same time, the levels of IL-6 and TNF-α in serum were determined. Results The efficacies in the control and treatment groups were 80.0% and 93.3%, respectively, and there were differences between two groups (P < 0.05). After treatment, abdominal pain score, diarrhea score, the abnormal rate of stool characteristics, and defecating frequency in two groups were significantly decreased (P < 0.05), and these indicators in treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of IL-6 and TNF-α in serum in two groups were obviously reduced (P < 0.05), and these indicators in treatment group were also lower than those in the control group (P < 0.05). Conclusions Compound Eosinophil-Lactobacillus Tablets combined with Trimebutine Maleate Tablets has significant clinical efficacy and good safety, which has a certain clinical application value.